Literature DB >> 12721896

Measles incidence before and after mass vaccination campaigns in Burkina Faso.

Chantal Kambiré1, M Kader Konde, André Yaméogo, Sylvestre R M Tiendrébéogo, Rasmata Traoré Ouédraogo, Mac W Otten, K Lisa Cairns, Patrick L F Zuber.   

Abstract

Burkina Faso conducted mass measles vaccination campaigns among children aged 9 months to 4 years during December 1998 and December 1999. The 1998 campaign was limited to six cities and towns, while the 1999 campaign was nationwide. The last year of explosive measles activity in Burkina Faso was 1996. Measles surveillance data suggest that the 1998 urban campaigns did not significantly impact measles incidence. After the 1999 national campaign, the total case count decreased during 2000 and 2001. However, 68% of measles cases occurred among children aged 5 years or older who were not included in the mass vaccination strategy. During 2000 and 2001, areas with high measles incidence were characterized by low population density and presence of mobile and poor populations. Measles control strategies in Sahelian Africa must balance incomplete impact on virus circulation with cost of more aggressive strategies that include older age groups.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721896     DOI: 10.1086/368043

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  Time is of the essence: exploring a measles outbreak response vaccination in Niamey, Niger.

Authors:  R F Grais; A J K Conlan; M J Ferrari; A Djibo; A Le Menach; O N Bjørnstad; B T Grenfell
Journal:  J R Soc Interface       Date:  2008-01-06       Impact factor: 4.118

2.  Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.

Authors:  Man Ki Song; Christofer J Vindurampulle; Alejandra V E Capozzo; Jeffrey Ulmer; John M Polo; Marcela F Pasetti; Eileen M Barry; Myron M Levine
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.